Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-138695 · Präparat HOS-098240
11
Antacids (e.g., Not studied. Significant
aluminium decreases in rilpivirine
magnesium hydroxide, plasma concentrations are
and/or calcium expected
carbonate)/ Rilpivirine (reduced absorption due to
gastric pH increase).
Calcium supplements/ Dolutegravir The combination of dolutegravir/rilpivirine and
Dolutegravir1 AUC 39% supplements should be used with particular
Cmax 37% caution. Calcium supplements, iron supplements or
C24 39% multivitamins should be co-administered at the
(Complex binding to same time as dolutegravir/rilpivirine with a meal.
polyvalent ions).
Iron supplements/ Dolutegravir If calcium supplements, iron supplements or
Dolutegravir1 AUC 54% multivitamins cannot be taken at the same time as
Cmax 57% dolutegravir/rilpivirine, these supplements should
C24 56% be taken well separated in time from the
(Complex binding to administration of dolutegravir/rilpivirine
polyvalent ions). (minimum 6 hours before or 4 hours after).
Multivitamin/ Dolutegravir
Dolutegravir1 AUC 33%
Cmax 35%
C24 32%
(Complex binding to
polyvalent ions).
Corticosteroids
Prednisone/ Dolutegravir No dose adjustment is required.
Dolutegravir1 AUC 11%
Cmax 6%
Cτ 17%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): magnesium hydroxide (HOS-088789) calcium (HOS-085615) iron (HOS-085656) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage 4107f13df8307fb7fb4a77149022c0fbfd9ed09a3dd5934b022a0098483e625d · Zeichen 17741–19665 im Abschnitt
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-138696 · Präparat HOS-098240
Prednisone/ Rilpivirine
Rilpivirine (Not studied)
Dexamethasone/ Dolutegravir Co-administration may cause significant decreases
Dolutegravir (Not studied) in rilpivirine plasma concentrations. This may
result in loss of therapeutic effect of
Dexamethasone/ Rilpivirine dolutegravir/rilpivirine. Co-administration of
Rilpivirine Not studied. Dose dependent dolutegravir/rilpivirine with systemic
(systemic, except for decreases in rilpivirine dexamethasone is contraindicated (except as a
single dose use) plasma concentrations are single dose) see section 4.3. Alternatives should be
expected considered, particularly for long-term use.
(induction of CYP3A
enzymes).
Antidiabetics
Metformin/ Metformin A dose adjustment of metformin should be
Dolutegravir1 AUC 79% considered when starting and stopping co-
Cmin NA administration of dolutegravir/rilpivirine with
Cmax 66% metformin, to maintain glycaemic control. In
patients with moderate renal impairment a dose
Metformin/ Metformin adjustment of metformin should be considered
Rilpivirine1 AUC ↔ when co-administered with dolutegravir, because
Cmin NA of the increased risk for lactic acidosis in patients
Cmax ↔ with moderate renal impairment due to increased
metformin concentration (section 4.4).
Antimycobacterials
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dexamethasone (HOS-084535) prednisone (HOS-084526) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage f664e4ca76e642535617d6266d1f245162a175d3f59abb6d51bd4b71ae484db9 · Zeichen 19667–21692 im Abschnitt
Wechselwirkungen · Ebvallo
Ebvallo 2.8 × 107 – 7.3 × 107 cells/mL dispersion for injection · Abschnitt 4.5 · PDF-Seite 6
HOS-139982 · Präparat HOS-098428
For patients receiving chronic corticosteroid therapy, the dose of these drugs should be reduced as
much as is clinically safe and appropriate; recommended no greater than 1 mg/kg per day of
prednisone or equivalent. Ebvallo has not been evaluated in patients receiving corticosteroid doses
greater than 1 mg/kg per day of prednisone or equivalent.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T09:37:00Z · SHA-256 b6b70030408178a0a00d53670d3028d050f247217c320de44f31caafbd3ecd0c · Passage 9763558761f9df63dbe79fe23bf9496fa92c16b2960c2133a835e052b1ea6842 · Zeichen 428–776 im Abschnitt
Wechselwirkungen · Imfinzi
IMFINZI 50 mg/ml concentrate for solution for infusion. · Abschnitt 4.5 · PDF-Seite 14
HOS-141785 · Präparat HOS-098696
The use of systemic corticosteroids or immunosuppressants before starting durvalumab, except
physiological dose of systemic corticosteroids (≤ 10 mg/day prednisone or equivalent), is not
recommended because of their potential interference with the pharmacodynamic activity and efficacy
of durvalumab. However, systemic corticosteroids or other immunosuppressants can be used after
starting durvalumab to treat immune-related adverse reactions (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-18T16:10:00Z · SHA-256 2aea150cfee5fbe605596424a5c30efdb4cdb269005b61f75a72ebb78beb905f · Passage 58501d3d208512c13e83fa9c09b3c41512658a0671e34e8474568aea93273d27 · Zeichen 0–461 im Abschnitt
Wechselwirkungen · Libtayo
LIBTAYO 350 mg concentrate for solution for infusion. · Abschnitt 4.5 · PDF-Seite 10
HOS-142294 · Präparat HOS-098800
No pharmacokinetic (PK) drug-drug interaction studies have been conducted with cemiplimab.
The use of systemic corticosteroids or immunosuppressants before starting cemiplimab, except for
physiological doses of systemic corticosteroid (≤ 10 mg/day prednisone or equivalent), should be
avoided because of their potential interference with the pharmacodynamic activity and efficacy of
cemiplimab. However, systemic corticosteroids or other immunosuppressants can be used after
starting cemiplimab to treat immune-mediated adverse reactions (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-10T09:43:00Z · SHA-256 e26a4d46dee107273416cff167125ea4a2d57ae4635bf68f860ceb24b87bd4b6 · Passage 2fccc0f9db7522e387893eefcb3544b0749b21f59993342a1385269bb9a93a01 · Zeichen 0–556 im Abschnitt
Wechselwirkungen · Dovato
Dovato 50 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-142843 · Präparat HOS-098886
11
Multivitamins (containing Dolutegravir during fasted conditions. In fed state, the
calcium, iron and magnesium) AUC 33% changes in exposure following intake
/Dolutegravir Cmax 35% together with calcium or iron
(fasted intake) C24 32% supplements were modified by the food
(Complex binding to effect, resulting in an exposure similar to
polyvalent ions) that obtained with dolutegravir
administered in the fasted state.
Proton pump inhibitors
Omeprazole Dolutegravir No dosage adjustment necessary.
Corticosteroids
Prednisone/Dolutegravir Dolutegravir No dose adjustment is necessary.
AUC 11%
Cmax 6%
Cτ 17%
Antidiabetics
Metformin/Dolutegravir Metformin A dose adjustment of metformin should
Dolutegravir be considered when starting and
When co-administered stopping coadministration of Dovato
with dolutegravir 50 mg with metformin, to maintain glycaemic
QD: control. In patients with moderate renal
Metformin impairment a dose adjustment of
AUC 79% metformin should be considered when
Cmax 66% coadministered with Dovato, because of
When co-administered the increased risk for lactic acidosis in
with dolutegravir 50 mg patients with moderate renal impairment
BID: due to increased metformin
Metformin concentration (section 4.4).
AUC 145 %
Cmax 111%
Herbal products
St. John’s wort/Dolutegravir Dolutegravir The recommended dose of dolutegravir
(Not studied, decrease is 50 mg twice daily when co-
expected due to induction administered with St. John’s wort. As
of UGT1A1 and CYP3A Dovato is a fixed-dose tablet, an
enzymes, a similar additional 50 mg tablet of dolutegravir
reduction in exposure as should be administered, approximately
observed with 12 hours after Dovato for the duration of
carbamazepine is the St. John’s wort co-administration (a
expected). separate formulation of dolutegravir is
available for this dose adjustment, see
section 4.2).
Oral contraceptives
Ethinyl estradiol (EE) and Effect of dolutegravir: Dolutegravir had no pharmacodynamic
Norgestromin EE effect on Luteinizing Hormone (LH),
(NGMN)/Dolutegravir AUC 3% Follicle Stimulating Hormone (FSH) and
Cmax 1% progesterone. No dose adjustment of
oral contraceptives is necessary when
Effect of dolutegravir: co-administered with Dovato.
NGMN
AUC 2%
Cmax 11%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) follicle stimulating hormone (HOS-123034) carbamazepine (HOS-085618) ethinyl estradiol (HOS-088135) calcium (HOS-085615) iron (HOS-085656) luteinizing hormone (HOS-090752) magnesium (HOS-085165) prednisone (HOS-084526) metformin (HOS-091032) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T01:22:00Z · SHA-256 9ebb38c4be2b7abc7ba2934afb44e75aa1d6b86e46ecc069e568b333119de792 · Passage 2f6766181d55d8513097e83ade1239e25819402a3fdabb28f23368f6b03130e3 · Zeichen 23358–27625 im Abschnitt
Gegenanzeigen · Qdenga
Qdenga powder and solvent for solution for injection Qdenga powder and solvent for solution for injection in pre-filled syringe Dengue tetravalent vaccine (live, attenuated) · Abschnitt 4.3 · PDF-Seite 3
HOS-144692 · Präparat HOS-099244
• Individuals with congenital or acquired immune deficiency, including those receiving
immunosuppressive therapies such as high doses of systemic corticosteroids (e.g. 20 mg/day
or 2 mg/kg body weight/day of prednisone for 2 weeks or more) within 4 weeks prior to
vaccination, or any other medicinal product with known immunosuppressive properties
including chemotherapy. The time to avoid vaccination after immunosuppressive treatment
should be considered on an individual basis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-04T12:15:00Z · SHA-256 f0e1da92d206a9ab00b8eab81d75d970f8b633f9b7c5ab9ec49d461a2b3745c5 · Passage 1107e334a7cf06a007557d5df000505cafae5eea05e09c0dabbd6e2505ac42aa · Zeichen 165–703 im Abschnitt
Gegenanzeigen · Abiraterone Mylan
Abiraterone Mylan 500 mg film-coated tablets Abiraterone Mylan 1000 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4
HOS-146755 · Präparat HOS-099564
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Women who are or may potentially be pregnant (see section 4.6).
• Severe hepatic impairment [Child-Pugh Class C (see sections 4.2, 4.4 and 5.2)].
• Abiraterone Mylan with prednisone or prednisolone is contraindicated in combination with
Ra-223.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisolone (HOS-086337) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T13:57:00Z · SHA-256 a224b8fadc2ad3e1b1af874d8687b8e3d6bb14c5f714b2308f5ba81c1b78da11 · Passage 8ab39b3717acb9aefaee271878e7c5c259f2b6dac70c95bf4f577bb585461021 · Zeichen 0–362 im Abschnitt
Wechselwirkungen · Abiraterone Mylan
Abiraterone Mylan 500 mg film-coated tablets Abiraterone Mylan 1000 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-146763 · Präparat HOS-099564
Potential to affect exposures to other medicinal products
Abiraterone is an inhibitor of the hepatic drug-metabolising enzymes CYP2D6 and CYP2C8. In a
study to determine the effects of abiraterone acetate (plus prednisone) on a single dose of the CYP2D6
substrate dextromethorphan, the systemic exposure (AUC) of dextromethorphan was increased
approximately 2.9 fold. The AUC24 for dextrorphan, the active metabolite of dextromethorphan,
increased approximately 33%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dextromethorphan (HOS-109265) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T13:57:00Z · SHA-256 a224b8fadc2ad3e1b1af874d8687b8e3d6bb14c5f714b2308f5ba81c1b78da11 · Passage 33ddbc12d982f1a0597e570a303e0abf4124d1cb5ea2c93c49c780baf063f1c0 · Zeichen 1096–1562 im Abschnitt
Wechselwirkungen · Camzyos
CAMZYOS 2.5 mg hard capsules CAMZYOS 5 mg hard capsules CAMZYOS 10 mg hard capsules CAMZYOS 15 mg hard capsules · Abschnitt 4.5 · PDF-Seite 12–13
HOS-147612 · Präparat HOS-099694
12
Concomitant CYP2C19 poor metaboliser phenotype* CYP2C19 intermediate,
medicinal product normal, rapid and ultra-rapid
metaboliser phenotype
Moderate or weak No dose adjustment. Monitor LVEF 4 weeks Initiating the dose of moderate
CYP2C19 inducer (e.g., later, and then resume the patient’s monitoring or weak inducer while on
letermovir, and titration schedule. Adjust mavacamten mavacamten treatment:
norethindrone, dose based on clinical assessment (see Monitor LVOT gradient and
prednisone) section 4.2). LVEF 4 weeks later. Adjust
mavacamten dose based on
clinical assessment and then
resume the patient’s monitoring
and titration schedule (see
section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): letermovir (HOS-090621) norethindrone (HOS-088136) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-02T15:36:00Z · SHA-256 9132b2e8e8aaa16319c50ba4cee221a3197217762e259ff316f0a88969d8e68f · Passage ac0f455fb9dbec1c2a20c198ced02b31278843f4265513c0e0bcb177c81bdecc · Zeichen 13724–15036 im Abschnitt
Wechselwirkungen · Tevimbra
Tevimbra 100 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 10
HOS-150205 · Präparat HOS-100272
The use of systemic corticosteroids and other immunosuppressants at baseline, before starting
tislelizumab, except for low doses of systemic corticosteroid (10 mg/day prednisone or equivalent),
should be avoided because of their potential interference with the pharmacodynamic activity and
efficacy of tislelizumab. However, systemic corticosteroids and other immunosuppressants can be
used after starting tislelizumab to treat immune-related adverse reactions (see section 4.4).
Corticosteroids can also be used as pre-medication when tislelizumab is used in combination with
chemotherapy, as antiemetic prophylaxis and/or to alleviate chemotherapy-related adverse reactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-24T10:58:00Z · SHA-256 b90d6b873189605f7e56ff04da9c6d2bfdef554be70d3337559ed5570f11f7fe · Passage 1945c3ee13135aa6dd13730ac78a9be7eab4257cd3219079934b5510a61d7cb9 · Zeichen 436–1112 im Abschnitt
Gegenanzeigen · Akeega
Akeega 50 mg/500 mg film-coated tablets Akeega 100 mg/500 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 6
HOS-150303 · Präparat HOS-100288
Akeega plus prednisone or prednisolone is contraindicated in combination with Ra-223 treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisolone (HOS-086337) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-17T15:30:00Z · SHA-256 1bec7f3e5f18e4fe578c0f49b6a9128776963f703a1a9503180dea643f434459 · Passage 14f97e11b04b555cd930e9aeb077794f90497e953622518e3963edef62a14dc9 · Zeichen 232–327 im Abschnitt
Wechselwirkungen · Akeega
Akeega 50 mg/500 mg film-coated tablets Akeega 100 mg/500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-150309 · Präparat HOS-100288
Effects of niraparib or abiraterone acetate on other medicinal products
CYP2D6 substrates
Abiraterone is an inhibitor of CYP2D6. In a clinical study to determine the effects of abiraterone
acetate plus prednisone (AAP) on a single dose of the CYP2D6 substrate dextromethorphan, the
systemic exposure (AUC) of dextromethorphan was increased approximately 2.9-fold. The AUC24 for
dextrorphan, the active metabolite of dextromethorphan, increased approximately 33%. Dose
reduction of medicinal products with a narrow therapeutic index that are metabolised by CYP2D6
should be considered. Examples of medicinal products metabolised by CYP2D6 include metoprolol,
propranolol, desipramine, venlafaxine, haloperidol, risperidone, propafenone, flecainide, codeine,
oxycodone and tramadol.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): niraparib (HOS-136825) propafenone (HOS-084530) codeine (HOS-090544) acetate (HOS-088133) desipramine (HOS-086249) flecainide (HOS-086203) oxycodone (HOS-109487) risperidone (HOS-086280) venlafaxine (HOS-086573) haloperidol (HOS-085602) propranolol (HOS-084529) dextromethorphan (HOS-109265) prednisone (HOS-084526) metoprolol (HOS-090094) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-17T15:30:00Z · SHA-256 1bec7f3e5f18e4fe578c0f49b6a9128776963f703a1a9503180dea643f434459 · Passage 704800110d63379fb341b1ca9221e58b93483aec5c2142b646bcbfc2ed920ac5 · Zeichen 1171–1951 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.